Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia

Nonfiction, Health & Well Being, Medical, Specialties, Internal Medicine, Hematology, Oncology
Cover of the book Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia by , Springer Japan
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9784431557142
Publisher: Springer Japan Publication: November 5, 2015
Imprint: Springer Language: English
Author:
ISBN: 9784431557142
Publisher: Springer Japan
Publication: November 5, 2015
Imprint: Springer
Language: English

Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia provides a comprehensive understanding of the recent molecular genetics of Chronic Myelogenous Leukemia (CML) and a characterization of the molecular targets for drug development. Included are therapeutic implications, diagnosis, and prognosis for understanding and facilitating daily practice in the management of patients with CML.

Understanding of the pathogenesis and therapy of hematological malignancies such as CML has grown significantly in recent years. This development owe much to the progress in molecular biology and now makes a major contribution to diagnosis and to treatment that pharmacologically targets the molecular events of CML. Molecular targeting therapy with newly developed agents such as small molecules and antibodies for hematological malignancies are being discovered after years of research. Some of these, including tyrosine kinase inhibitors such as imatinib, nilotinib, and dasatinib, lead to increased survival rates and improved therapies. With the opinion leaders of basic and clinical research in the field as authors, this book reviews recent advances in the biology of CML.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia provides a comprehensive understanding of the recent molecular genetics of Chronic Myelogenous Leukemia (CML) and a characterization of the molecular targets for drug development. Included are therapeutic implications, diagnosis, and prognosis for understanding and facilitating daily practice in the management of patients with CML.

Understanding of the pathogenesis and therapy of hematological malignancies such as CML has grown significantly in recent years. This development owe much to the progress in molecular biology and now makes a major contribution to diagnosis and to treatment that pharmacologically targets the molecular events of CML. Molecular targeting therapy with newly developed agents such as small molecules and antibodies for hematological malignancies are being discovered after years of research. Some of these, including tyrosine kinase inhibitors such as imatinib, nilotinib, and dasatinib, lead to increased survival rates and improved therapies. With the opinion leaders of basic and clinical research in the field as authors, this book reviews recent advances in the biology of CML.

More books from Springer Japan

Cover of the book Ecological Impacts of Tsunamis on Coastal Ecosystems by
Cover of the book Applied Matrix and Tensor Variate Data Analysis by
Cover of the book Agent-Based Approaches in Economic and Social Complex Systems VIII by
Cover of the book Resilient Asia by
Cover of the book Integrative Observations and Assessments by
Cover of the book HCV/Oxidative Stress and Liver Disease by
Cover of the book The Smart City and the Co-creation of Value by
Cover of the book Regional Economic Analysis of Power, Elections, and Secession by
Cover of the book Mathematical and Computational Analyses of Cracking Formation by
Cover of the book Hometown Investment Trust Funds by
Cover of the book Corrosion Control and Surface Finishing by
Cover of the book Introduction to Singularities by
Cover of the book Cardio-aortic and Aortic Surgery by
Cover of the book The Liquid Crystal Display Story by
Cover of the book Trust by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy